| Item Type | Name |
|
Concept
|
Antibodies, Neoplasm
|
|
Concept
|
Antibodies, Viral
|
|
Concept
|
Antibodies, Anti-Idiotypic
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Genetic Engineering
|
|
Concept
|
Protein Engineering
|
|
Concept
|
Antibodies, Blocking
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Antibodies
|
|
Academic Article
|
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
|
|
Academic Article
|
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
|
|
Academic Article
|
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
|
|
Academic Article
|
CD28 is not required for c-Jun N-terminal kinase activation in T cells.
|
|
Academic Article
|
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
|
|
Academic Article
|
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma.
|
|
Academic Article
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
|
|
Academic Article
|
On the TRAIL toward death receptor-based cancer therapeutics.
|
|
Academic Article
|
Phase I/II trial of tremelimumab in patients with metastatic melanoma.
|
|
Academic Article
|
Induction of cytotoxic granules in human memory CD8+ T cell subsets requires cell cycle progression.
|
|
Academic Article
|
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
|
|
Academic Article
|
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
|
|
Academic Article
|
Use of Cre-adenovirus and CAR transgenic mice for efficient deletion of genes in post-thymic T cells.
|
|
Academic Article
|
A designer ligand specific for Kv1.3 channels from a scorpion neurotoxin-based library.
|
|
Academic Article
|
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
|
|
Academic Article
|
Nakahara memorial lecture. Regulation of T lymphocyte responses: interactions among receptors.
|
|
Academic Article
|
Evidence implicating I region-restricted antigen presentation in alloantigen and nominal antigen recognition by a dual-reactive helper T lymphocyte clone.
|
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
|
Academic Article
|
"Anergy" of TH0 helper T lymphocytes induces downregulation of TH1 characteristics and a transition to a TH2-like phenotype.
|
|
Academic Article
|
Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone.
|
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
|
Academic Article
|
Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.
|
|
Academic Article
|
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
|
|
Academic Article
|
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
|
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
|
Academic Article
|
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature.
|
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
|
Academic Article
|
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
|
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
|
Academic Article
|
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
|
|
Academic Article
|
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma.
|
|
Academic Article
|
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
|
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
|
Academic Article
|
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
|
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
|
|
Academic Article
|
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
|
|
Academic Article
|
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.
|
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
|
|
Academic Article
|
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
|
|
Academic Article
|
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
|